Nifurtimox

Summary

Nifurtimox (CHEMBL290960) is an approved small molecule (ATC P01CC01); indicated across 6 conditions including trypanosomiasis and chagas disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: P01CC01
• Indications: 6 conditions
• Clinical trials: 9
• Chemistry: 287.29 Da · C10H13N3O5S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL290960
Name	Nifurtimox
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	6842999
ATC	P01CC01
Molecular formula	C10H13N3O5S
Molecular weight	287.29
InChIKey	ARFHIAQFJWUCFH-IZZDOVSWSA-N

SMILES: CC1CS(=O)(=O)CCN1/N=C/C2=CC=C(O2)[N+](=O)[O-]

IUPAC name: (E)-N-(3-methyl-1,1-dioxo-1,4-thiazinan-4-yl)-1-(5-nitrofuran-2-yl)methanimine

Also known as: BAY 2502, BAY A2502, BAY-2502, BAY-A2502, BAYER 2502, BAYER-2502, DNDI1613515, Lampit, Nifurtimox, Nifurtimoxum, nifurtimox, NIFURTIMOX

Patent coverage: 25 distinct patent families (37 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
trypanosomiasis	4	MONDO:0000940	DOID:10113
Chagas disease	4	MONDO:0001444	EFO:0008559
leishmaniasis	4	MONDO:0011989	EFO:0005044
human African trypanosomiasis	2	MONDO:0005459	EFO:0005225
neuroblastoma	1	MONDO:0005072	EFO:0000621

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2/PHASE3	2
PHASE2	2
PHASE1	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00146627	PHASE3	COMPLETED	Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis
NCT00330148	PHASE3	TERMINATED	Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis
NCT01685827	PHASE2/PHASE3	COMPLETED	Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2
NCT02369978	PHASE2/PHASE3	UNKNOWN	CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY)
NCT00601003	PHASE2	COMPLETED	Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
NCT03981523	PHASE2	COMPLETED	New Therapies and Biomarkers for Chagas Infection
NCT00486564	PHASE1	COMPLETED	Safety Study of Nifurtimox for Relapsed or Refractory Neuroblastoma
NCT02606864	PHASE1	COMPLETED	Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas’ Patients
NCT05477953	Not specified	NOT_YET_RECRUITING	An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother’s and Baby’s Health

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).